DrugsControl Media Services

News Detail

AstraZeneca COVID drug neutralizes Omicron sub-variants in study (21-03-2022)

Washington, 21 March 2022: AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study.


View Details
Source : Livemint

Related News